雅创医药技术有限公司(以下简称“雅创医药”)近日宣布,公司将在2023年欧洲肝脏研究协会年会(EASL
2023)上,以海报形式展示公司非酒精性脂肪性肝炎(NASH)管线上两个项目的临床前和临床研究最新进展。详情如下:
Hepagene Therapeutics,
Inc., a clinical stage
biopharmaceutical
company focusing on developing novel
therapies
for patients with
chronic liver diseases, today announced that
Hepagene will present
two posters highlighting the preclinical and
clinical development
for its two non-alcoholic steatohepatitis
(NASH)
programs at the
European Association for the Study of the
Liver
(EASL) Congress,
taking place in Vienna Austria, June 21-24,
2023. Details of the
presentation are as follows:
高度选择性的THRβ激动剂HPG7233
标题:HPG7233临床前特性:一种用于治疗非酒精性脂肪性肝炎有效、肝靶向的高选择性甲状腺激素受体激动剂
演示编号:391
分场主题:非酒精性脂肪性肝病(NAFLD):实验和病理生理学
主讲人:刘确博士
HPG7233是一款新型肝靶向的高选择性小分子THRβ激动剂,其机理旨在血清及肝脏脂肪代谢方面起到调节作用。前期临床前研究显示,HPG7233在体内外试验中表现出突出的活性以及高度选择性,在动物体内肝血比(L/P
Ratio)较大,有着显著的肝靶向特性;在药效模型中,展示了其优异的降低肝脏脂肪及血脂水平的能力,同时NAS出现显著性降低。为HPG7233进一步转入NAFLD和NASH临床研发提供了强有力的支持。
Highly Selective
THR-β
Agonist HPG7233
Title: Preclinical characterization of
HPG7233, a
potent,
liver-target and highly selective
thyroid
hormone receptor beta
agonist for nonalcoholic steatohepatitis
Presentation Number: 391
Session Title: NAFLD: Experimental and
pathophysiology
Presenting Author: Dr. Que Liu (Chief
Medical
Officer)
HPG7233 is a novel liver-targeted and
highly
selective small molecule
thyroid hormone receptor beta (THR-beta)
agonist
aimed at serum and
liver lipid metabolism.HPG7233
demonstrated
high
selectivity and
potency, great liver-enrichment and
liver-plasma
exposure profile in
rodent and non-rodent animals,
significant
reduction of liver index
and serological markers level, and
significant
reduction of NAS
score in NASH model. These results
provide
strong evidence to
support continuing efforts in HPG7233
development for NASH and
dyslipidemia indications.
新一代非胆汁酸结构FXR激动剂HPG1860
标题:HPG1860在NASH患者中的一项II期双盲、安慰剂对照、剂量范围研究
演示编号:383
分场主题:非酒精性脂肪性肝病(NAFLD):治疗
主讲人:Naim Alkhouri博士
RISE研究(NCT05338034)是一项多中心、随机、双盲、安慰剂对照的临床2a试验,主要评估药物的安全性、耐受性、有效性以及药代动力学特征。研究共招募了87例成年非肝硬化的NASH患者,每日一次口服HPG1860
3 mg,5 mg,8
mg或安慰剂,连续给药12周。研究主要目的是评价HPG1860的安全性和耐受性,次要研究终点则包括:通过MRI-PDFF评估患者经治疗后较基线的肝脏脂肪含量(LFC)变化,ALT水平,HPG1860的血药浓度,药效动力学参数以及NASH生物标志物。
在RISE研究中,受试者经HPG1860给药12周后总体耐受性良好,绝大部分的不良事件为轻度至中度。在3
mg,5 mg和8
mg给药组中,治疗相关的瘙痒发生率仅分别为9.1%,9.5%及27.3%。不同剂量组中HPG1860均未显著增加低密度脂蛋白胆固醇的水平。经HPG1860给药12周后,3mg和8mg给药组的受试者肝脏脂肪含量较基线均显著降低。
“HPG7233是一种每日一次口服的新型
THR β
激动剂,临床前研究预示它在临床上具有更强的疗效和良好的安全性。我们期待HPG7233今年下半年进行临床研究。”
雅创首席医学官刘确博士说。
“HPG1860是不同于第一代胆汁酸型奥贝胆酸(OCA)的新一代非胆汁酸FXR激动剂。
HPG1860在已经完成的临床II期实验中显示出与 OCA
相比更好的安全性及药效。我们相信,HPG1860与新型THR-β 激动剂
HPG7233 联合使用,将显著提高疗效,同时保持良好的安全性。”
截止发稿前,HPG1860已经完成临床II期的研究,展现出良好的安全性以及对于肝脏脂肪含量的显著改善。基于HPG1860优异的联合用药潜力,以及HPG7233已完成的临床前数据和注册申报计划,雅创医药正在积极准备HPG7233
NASH单药临床以及HPG1860与HPG7233联合用药的NASH临床研究。
Next Generation Non-Bile
Acid FXR Agonist HPG1860
Title: HPG1860 in
patients with NASH: a phase
II
double-blind,
placebo-controlled, dose-ranging study
Presentation Number:
383
Session: NAFLD:
Therapy
Presenting Author:
Dr.
Naim Alkhouri
(Principal
Investigator)
This phase 2 study
(NCT05338034) is a
multi-center, randomized,
double-blind, placebo-controlled,
parallel-group
clinical trial
(RISE trial) to evaluate the safety,
tolerability, efficacy, and
pharmacokinetics of orally administered
HPG1860
tablet at doses of 3
mg, 5 mg and 8 mg in 87 adult patients
with
presumed non-cirrhotic
non-alcoholic steatohepatitis (NASH).
The
primary objective of the
clinical trial was to evaluate the
safety
and
tolerability of
HPG1860. Secondary endpoints included
percent
change from baseline
in liver fat content (LFC) measured by
MRI
proton density fat
fraction (MRI-PDFF), plasma
pharmacokinetics
of
HPG1860,
pharmacodynamic parameters, and serum
NASH
biomarkers.
In the RISE trial, once daily
administration
of
HPG1860 for 12 weeks
was generally well tolerated and most
AEs
were
mild and moderate.
Treatment-related pruritus occurred in
9.1%,
9.5%, 27.3% of patients
in the 3, 5, and 8mg cohort respectively
and
no
significant change
in LDL cholesterol (LDL-C) was observed
in
the 3
mg, 5 mg and 8 mg
HPG1860 cohorts. Meanwhile, significant
reductions of mean relative
changes in LFC at week 12 were observed
in 3
mg
and 8 mg HPG1860
cohorts. Treatment of HPG1860 also
reduced
liver
enzymes including
ALT and GGT.
“We are excited
about
the great progress of
HPG7233, a novel once
daily THR beta agonist, which may have
robust
efficacy with benign
safety profile in clinics. The compound
is
on
track for a Phase 1
study in the second half this year.”
said
Dr.
Que Liu, CMO of
Hepagene. “HPG1860 is a new generation
of
non-bile acid FXR agonist
which is different from first generation
bile
acid type obeticholic
acid (OCA). HPG1860 has shown liver
enrichment
profile in
preclinical studies and displayed robust
efficacy with much better
safety profile vs OCA in clinical
settings.
We
believe that HPG1860
in combination with HPG7233, a novel
THR-beta
agonist, will
significantly improve efficacy while
maintaining
benign safety
profile”.
In summary, given
its
significant improvement
in
LFC and a benign
safety profile in NASH patients, HPG1860
has
shown favorable
risk-benefit data to support clinical
development of combination
therapy. Combined with favorable
pharmacology,
pharmacokinetic and
preclinical safety profile of HPG7233,
the
company plans to file an
IND for NASH around the third quarter of
this
year and is actively
planning the combination study (HPG1860
and
HPG7233) for NASH as
well as HPG 7233 monotherapy for NASH
and
dyslipidemia indications.
关于雅创医药
雅创医药是一家拥有临床阶段产品、全球化布局的生物制药公司,致力于非酒精性脂肪性肝炎(NASH)、病毒性乙型肝炎(HBV)、肝癌或晚期实体瘤等疾病领域创新药的研发及商业化,以解决未被满足的国内外临床需求。。
欲知更多资讯或沟通合作机会,请垂询:陶女士
Investor@hepagene.com